| Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma S Darb-Esfahani, CA Kunze, H Kulbe, J Sehouli, S Wienert, J Lindner, ... Oncotarget 7 (2), 1486, 2015 | 285 | 2015 |
| Sentinel node mapping in cervical and endometrial cancer: indocyanine green versus other conventional dyes—a meta-analysis I Ruscito, ML Gasparri, EI Braicu, F Bellati, L Raio, J Sehouli, MD Mueller, ... Annals of surgical oncology 23, 3749-3756, 2016 | 204 | 2016 |
| An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity J Wynendaele, A Böhnke, E Leucci, SJ Nielsen, I Lambertz, S Hammer, ... Cancer research 70 (23), 9641-9649, 2010 | 203 | 2010 |
| GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis O Cabral-Marques, A Marques, LM Giil, R De Vito, J Rademacher, ... Nature communications 9 (1), 5224, 2018 | 179 | 2018 |
| Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort RY Zang, P Harter, DS Chi, J Sehouli, R Jiang, CG Tropé, A Ayhan, ... British journal of cancer 105 (7), 890-896, 2011 | 160 | 2011 |
| Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance—a study of the OVCAD consortium E Obermayr, DC Castillo-Tong, D Pils, P Speiser, I Braicu, T Van Gorp, ... Gynecologic oncology 128 (1), 15-21, 2013 | 150 | 2013 |
| A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection WJ Tian, DS Chi, J Sehouli, CG Tropé, R Jiang, A Ayhan, G Cormio, ... Annals of surgical oncology 19, 597-604, 2012 | 149 | 2012 |
| The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma—analysis of patient data in the … G Hofstetter, N Concin, I Braicu, R Chekerov, J Sehouli, I Cadron, ... Gynecologic oncology 131 (1), 15-20, 2013 | 141 | 2013 |
| Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA–IV: analysis of the OVCAD data S Polterauer, I Vergote, N Concin, I Braicu, R Chekerov, S Mahner, ... International Journal of Gynecologic Cancer 22 (3), 2012 | 139 | 2012 |
| Stable expansion of high‐grade serous ovarian cancer organoids requires a low‐Wnt environment K Hoffmann, H Berger, H Kulbe, S Thillainadarasan, HJ Mollenkopf, ... The EMBO journal 39 (6), e104013, 2020 | 135 | 2020 |
| BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients–a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD) I Ruscito, D Dimitrova, I Vasconcelos, K Gellhaus, T Schwachula, F Bellati, ... European journal of cancer 50 (12), 2090-2098, 2014 | 107 | 2014 |
| A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer-a study of the OVCAD consortium D Pils, D Tong, G Hager, E Obermayr, S Aust, G Heinze, M Kohl, ... Bmc Cancer 13, 1-13, 2013 | 106 | 2013 |
| Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome C Fotopoulou, K Savvatis, EI Braicu, V Brink-Spalink, S Darb-Esfahani, ... Gynecologic oncology 119 (2), 285-290, 2010 | 105 | 2010 |
| Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial R Chekerov, F Hilpert, S Mahner, A El-Balat, P Harter, N De Gregorio, ... The Lancet Oncology 19 (9), 1247-1258, 2018 | 103 | 2018 |
| Chronic Chlamydia infection in human organoids increases stemness and promotes age-dependent CpG methylation M Kessler, K Hoffmann, K Fritsche, V Brinkmann, HJ Mollenkopf, O Thieck, ... Nature Communications 10 (1), 1194, 2019 | 100 | 2019 |
| Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation C Fotopoulou, R Zang, M Gultekin, D Cibula, A Ayhan, D Liu, R Richter, ... Annals of surgical oncology 20, 1348-1354, 2013 | 100 | 2013 |
| Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses A Vanderstichele, P Busschaert, D Smeets, C Landolfo, ... Clinical Cancer Research 23 (9), 2223-2231, 2017 | 99 | 2017 |
| Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients J Sehouli, R Richter, EI Braicu, KJ Bühling, M Bahra, P Neuhaus, ... Journal of surgical oncology 102 (6), 656-662, 2010 | 99 | 2010 |
| Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers EI Braicu, J Sehouli, R Richter, K Pietzner, C Denkert, C Fotopoulou British journal of cancer 105 (12), 1818-1824, 2011 | 95 | 2011 |
| Expression of IL-10 in patients with ovarian carcinoma A Mustea, D Könsgen, EI Braicu, C Pirvulescu, P Sun, D Sofroni, ... Anticancer research 26 (2C), 1715-1718, 2006 | 95 | 2006 |
